Laurence Slama1, Xiuhong Li, Todd Brown, Lisa P Jacobson, Gilles Pialoux, Bernard Macatangay, Robert K Bolan, John Phair, Frank J Palella. 1. *Tenon Hospital, Division of Infectious Diseases, Pierre and Marie Curie University, Paris, France; †Department of Epidemiology and ‡Division of Endocrinology and Metabolism, John Hopkins University, Baltimore, MD; §School of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA; ‖L.A. Gay & Lesbian Center, Los Angeles, CA; and ¶Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL.
Abstract
BACKGROUND: Antiretroviral therapy (ART) regimens changes occur frequently among HIV-infected persons. Duration and type of initial highly active antiretroviral therapy (HAART) and factors associated with regimen switching were evaluated in the Multicenter AIDS Cohort Study. METHODS: Participants were classified according to the calendar period of HAART initiation: T1 (1996-2001), T2 (2002-2005), and T3 (2006-2009). Kaplan-Meier curves depicted time from HAART initiation to first regimen changes within 5.5 years. Cox proportional hazards regression models were used to examine factors associated with time to switching. RESULTS: Of 1009 participants, 796 changed regimen within 5.5 years after HAART initiation. The percentage of participants who switched declined from 85% during T1 to 49% in T3. The likelihood of switching in T3 decreased by 50% (P < 0.01) compared with T1 after adjustment for pre-HAART ART use, age, race, and CD4 count. Incomplete HIV suppression decreased over time (P < 0.01) but predicted switching across all time periods. Lower HAART adherence (≤95% of prescribed doses) was predictive of switching only in T1. In T2, central nervous system symptoms predicted switching [relative hazard (RH) = 1.7; P = 0.012]. Older age at HAART initiation was associated with increased switching in T1 (RH = 1.03 per year increase) and decreased switching in T2 (RH = 0.97 per year increase). CONCLUSIONS: During the first 15 years of the HAART era, initial HAART regimen duration lengthened and regimen discontinuation rates diminished. Both HIV RNA nonsuppression and poor adherence predicted switching before 2001 while side effects that were possibly ART related were more prominent during T2.
BACKGROUND: Antiretroviral therapy (ART) regimens changes occur frequently among HIV-infectedpersons. Duration and type of initial highly active antiretroviral therapy (HAART) and factors associated with regimen switching were evaluated in the Multicenter AIDS Cohort Study. METHODS:Participants were classified according to the calendar period of HAART initiation: T1 (1996-2001), T2 (2002-2005), and T3 (2006-2009). Kaplan-Meier curves depicted time from HAART initiation to first regimen changes within 5.5 years. Cox proportional hazards regression models were used to examine factors associated with time to switching. RESULTS: Of 1009 participants, 796 changed regimen within 5.5 years after HAART initiation. The percentage of participants who switched declined from 85% during T1 to 49% in T3. The likelihood of switching in T3 decreased by 50% (P < 0.01) compared with T1 after adjustment for pre-HAART ART use, age, race, and CD4 count. Incomplete HIV suppression decreased over time (P < 0.01) but predicted switching across all time periods. Lower HAART adherence (≤95% of prescribed doses) was predictive of switching only in T1. In T2, central nervous system symptoms predicted switching [relative hazard (RH) = 1.7; P = 0.012]. Older age at HAART initiation was associated with increased switching in T1 (RH = 1.03 per year increase) and decreased switching in T2 (RH = 0.97 per year increase). CONCLUSIONS: During the first 15 years of the HAART era, initial HAART regimen duration lengthened and regimen discontinuation rates diminished. Both HIV RNA nonsuppression and poor adherence predicted switching before 2001 while side effects that were possibly ART related were more prominent during T2.
Authors: T E Yamashita; J P Phair; A Muñoz; J B Margolick; R Detels; S J O'Brien; J W Mellors; S M Wolinsky; L P Jacobson Journal: AIDS Date: 2001-04-13 Impact factor: 4.177
Authors: C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding Journal: JAMA Date: 2000-01-19 Impact factor: 56.272
Authors: Mikaela Smit; Colette Smit; Ide Cremin; Geoffrey P Garnett; Timothy Hallett; Frank de Wolf Journal: AIDS Date: 2012-09-24 Impact factor: 4.177
Authors: A Mocroft; M Youle; A Moore; C A Sabin; S Madge; A C Lepri; M Tyrer; C Chaloner; D Wilson; C Loveday; M A Johnson; A N Phillips Journal: AIDS Date: 2001-01-26 Impact factor: 4.177
Authors: Juan A Arnaiz; Josep Mallolas; Daniel Podzamczer; Jan Gerstoft; Jens D Lundgren; Pedro Cahn; Gerd Fätkenheuer; Antonella D'Arminio-Monforte; Arnaldo Casiró; Peter Reiss; David M Burger; Michael Stek; José M Gatell Journal: AIDS Date: 2003-04-11 Impact factor: 4.177
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Cynthia A Kleeberger; Jennifer Buechner; Frank Palella; Roger Detels; Sharon Riddler; Rebecca Godfrey; Lisa P Jacobson Journal: AIDS Date: 2004-03-05 Impact factor: 4.177
Authors: Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: David B Hanna; Uriel R Felsen; Mindy S Ginsberg; Barry S Zingman; Robert S Beil; Donna C Futterman; Howard D Strickler; Kathryn Anastos Journal: AIDS Res Hum Retroviruses Date: 2016-03-17 Impact factor: 2.205
Authors: Rosario Martinez-Vega; Nicole L De La Mata; Nagalingeswaran Kumarasamy; Penh Sun Ly; Kinh Van Nguyen; Tuti P Merati; Thi Thanh Pham; Man Po Lee; Jun Yong Choi; Jeremy L Ross; Oon Tek Ng Journal: Antivir Ther Date: 2018
Authors: Anandi N Sheth; Ighovwerha Ofotokun; Kate Buchacz; Carl Armon; Joan S Chmiel; Rachel L D Hart; Rose Baker; John T Brooks; Frank J Palella Journal: J Acquir Immune Defic Syndr Date: 2016-01-01 Impact factor: 3.731
Authors: Ellen F Eaton; Ashutosh Tamhane; Thibaut Davy-Mendez; William C Mathews; Richard D Moore; Michael S Saag; Michael J Mugavero Journal: AIDS Date: 2018-01-28 Impact factor: 4.177
Authors: Ellen F Eaton; Ashutosh R Tamhane; Greer A Burkholder; James H Willig; Michael S Saag; Michael J Mugavero Journal: Open Forum Infect Dis Date: 2016-06-16 Impact factor: 3.835